Mortgage rates are near 7%, but buyers are making a comeback
Applications for mortgages in the latest week rose in spite of the 30-year rate inching up for the fourth week in a row to ...
Hedge funds are piling into the nuclear sector, Goldman Sachs’ analysis shows
Hedge funds are picking up stocks in nuclear power producers in seeking to capitalize on the artificial intelligence boom, ...
As Nvidia reports, here’s the history of what happens next after ten giant stocks outperform
The fund manager AllianceBernstein looked at periods where the top 10 stocks dominated over the last three decades.
Ex-Nomura staffer charged after attempted murder at elderly client’s home
A former Nomura employee has been charged with robbery, attempted murder, and arson of an inhabited building following an ...
Nvidia earnings: Stock near highs as AI fever faces its next big test
Nvidia is due to report fiscal third-quarter earnings after Wednesday's closing bell. MarketWatch will be breaking down the ...
Delta Air Lines sees opportunity in the “premium consumer” as it lays out long-term financial targets
Delta Air Lines Inc. DAL on Wednesday reiterated its fourth-quarter financial outlook as the carrier laid out long-term goals as part of its investor day. Delta said two-thirds of millennials are ...
Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again
Sage Therapeutics shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure. Sage shares, ...
Target’s stock plunges toward a one-year low after a triple-miss earnings report and downbeat outlook
Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore. Back To Top ...
Sage Therapeutics’ stock slides after trial of Huntington’s Disease treatment fails and company says it will end it
Sage Therapeutics Inc.’s stock SAGE fell 18% early Wednesday, after the company said a mid-stage trial of a treatment for cognitive impairment associated with Huntington’s Disease failed to meet its ...
Pfizer Gets European Approval of Hympavzi Hemophilia Drug
Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...
Delta Air Lines Well Positioned for Future Growth Due to High-Income Travelers, Millennials
Delta Air Lines said it is well positioned heading into the new year and beyond, expecting to improve its operating margins in the mid-teen percent range, as well as increase its per-share earnings by ...